P W Rosario1, S Purisch. 1. Department of Thyroid, Endocrinology Service, Santa Casa de Belo Horizonte, Minas Gerais, Brazil. pedrorosario@globo.com
Abstract
OBJECTIVE: To evaluate a highly sensitive thyroglobulin (Tg) assay [functional sensitivity (FS): 0.1 ng/ml] (Tg-ICMA) in low-risk patients with known Tg on T4 < or = 1 ng/ml measured by a traditional assay (FS: 1 ng/ml) (Tg-IRMA). METHODS: Tg-ICMA was measured in serum samples stored at -70 degrees C. Samples were obtained 6 months or more after total thyroidectomy and remnant ablation with (131)I, during L-T4 therapy (TSH < 0.4 mIU/l). All patients had well-differentiated and completely resected tumours, no ectopic uptake on post-therapy whole-body scans and were considered to be at low risk for recurrence. On the occasion of collection and retesting for this study, Tg-IRMA was < or = 1 ng/ml in all samples and no antibody interference was observed. RESULTS: Tg-ICMA < or = 0.1 ng/ml was observed in 130/178 (73%) patients and recurrence was diagnosed in only 1/130 (0.8%). Tg-IRMA measured after L-T4 withdrawal was > 1 ng/ml in 5/130 (3.8%) patients. Forty-eight (27%) patients had Tg-ICMA > 0.1 ng/ml (0.12-1.6 ng/ml) and recurrence was diagnosed in 5/48 (10.5%). Tg-IRMA measured after L-T4 withdrawal was > 1 ng/ml in 20/48 (41.6%) patients. A negative predictive value of 100% was achieved with Tg-ICMA on T4 < or = 0.1 ng/ml combined with neck ultrasonography (US) or with stimulated Tg-IRMA < or = 1 ng/ml. CONCLUSIONS: Patients at low risk for recurrence with undetectable Tg on T4 measured by a highly sensitive assay (FS: 0.1 ng/ml) in the absence of antibody interference and with a negative sensitive neck US do not need to be submitted to Tg stimulation. Recurrence is rare in these cases and only a minority of patients convert to stimulated Tg > 1-2 ng/ml.
OBJECTIVE: To evaluate a highly sensitive thyroglobulin (Tg) assay [functional sensitivity (FS): 0.1 ng/ml] (Tg-ICMA) in low-risk patients with known Tg on T4 < or = 1 ng/ml measured by a traditional assay (FS: 1 ng/ml) (Tg-IRMA). METHODS: Tg-ICMA was measured in serum samples stored at -70 degrees C. Samples were obtained 6 months or more after total thyroidectomy and remnant ablation with (131)I, during L-T4 therapy (TSH < 0.4 mIU/l). All patients had well-differentiated and completely resected tumours, no ectopic uptake on post-therapy whole-body scans and were considered to be at low risk for recurrence. On the occasion of collection and retesting for this study, Tg-IRMA was < or = 1 ng/ml in all samples and no antibody interference was observed. RESULTS: Tg-ICMA < or = 0.1 ng/ml was observed in 130/178 (73%) patients and recurrence was diagnosed in only 1/130 (0.8%). Tg-IRMA measured after L-T4 withdrawal was > 1 ng/ml in 5/130 (3.8%) patients. Forty-eight (27%) patients had Tg-ICMA > 0.1 ng/ml (0.12-1.6 ng/ml) and recurrence was diagnosed in 5/48 (10.5%). Tg-IRMA measured after L-T4 withdrawal was > 1 ng/ml in 20/48 (41.6%) patients. A negative predictive value of 100% was achieved with Tg-ICMA on T4 < or = 0.1 ng/ml combined with neck ultrasonography (US) or with stimulated Tg-IRMA < or = 1 ng/ml. CONCLUSIONS:Patients at low risk for recurrence with undetectable Tg on T4 measured by a highly sensitive assay (FS: 0.1 ng/ml) in the absence of antibody interference and with a negative sensitive neck US do not need to be submitted to Tg stimulation. Recurrence is rare in these cases and only a minority of patients convert to stimulated Tg > 1-2 ng/ml.
Authors: Cláudia C D Nakabashi; Teresa S Kasamatsu; Felipe Crispim; Claudia A Yamazaki; Cléber P Camacho; Danielle M Andreoni; Rosalia P Padovani; Elza S Ikejiri; Maria C O M Mamone; Flávia C Aldighieri; Jairo Wagner; Jairo T Hidal; José G H Vieira; Rosa P M Biscolla; Rui M B Maciel Journal: Eur Thyroid J Date: 2014-03-12
Authors: A Polachek; D Hirsch; G Tzvetov; S Grozinsky-Glasberg; I Slutski; J Singer; R Weinstein; I Shimon; C A Benbassat Journal: J Endocrinol Invest Date: 2011-05-30 Impact factor: 4.256
Authors: A Flores-Rebollar; I Pérez-Díaz; S Lagunas-Bárcenas; B García-Martínez; R Rivera-Moscoso; R Fagundo-Sierra Journal: Acta Otorhinolaryngol Ital Date: 2018-06 Impact factor: 2.124
Authors: M G Castagna; H P Tala Jury; C Cipri; V Belardini; C Fioravanti; L Pasqui; F Sestini; A Theodoropoulou; F Pacini Journal: J Endocrinol Invest Date: 2011-03-07 Impact factor: 4.256
Authors: M Sahin; B I Aydoğan; E Özkan; R Emral; S Güllü; M F Erdogan; D Çorapçıoğlu Journal: Acta Endocrinol (Buchar) Date: 2021 Jul-Sep Impact factor: 0.877